https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-07-27 / Pigment Cell Melanoma Res 2010 Oct;23(5):607-19
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-07-27 / Pigment Cell Melanoma Res 2010 Oct;23(5):607-192010-07-27 00:00:002010-07-27 00:00:00Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-07-19 / Vaccine 2010 Jul;28(32):5153-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-07-19 / Vaccine 2010 Jul;28(32):5153-602010-07-19 00:00:002019-02-15 08:40:17Human myeloid dendritic cells for cancer therapy: does maturation matter?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-07-14 / Proc. Natl. Acad. Sci. U.S.A. 2010 Aug;107(31):13824-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-07-14 / Proc. Natl. Acad. Sci. U.S.A. 2010 Aug;107(31):13824-92010-07-14 00:00:002019-02-15 08:45:27Induction of complete and molecular remissions in acute myeloid leukemia by Wilms‘ tumor 1 antigen-targeted dendritic cell vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-07-07 / Br. J. Haematol. 2010 Sep;150(5):554-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-07-07 / Br. J. Haematol. 2010 Sep;150(5):554-642010-07-07 00:00:002019-02-15 08:50:54Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-06-29 / J Oncol 2010;2010:179491
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-06-29 / J Oncol 2010;2010:1794912010-06-29 00:00:002019-02-15 08:53:21Advances in cellular therapy for the treatment of thyroid cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-06-08 / Cancer Immunol. Immunother. 2010 Sep;59(9):1295-312
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-06-08 / Cancer Immunol. Immunother. 2010 Sep;59(9):1295-3122010-06-08 00:00:002019-02-15 08:50:10Anti-HER2 vaccines: new prospects for breast cancer therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-06-01 / Expert Opin Biol Ther 2010 Jun;10(6):983-91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-06-01 / Expert Opin Biol Ther 2010 Jun;10(6):983-912010-06-01 00:00:002019-02-15 08:48:35INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-06-01 / Expert Rev Gastroenterol Hepatol 2010 Jun;4(3):345-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-06-01 / Expert Rev Gastroenterol Hepatol 2010 Jun;4(3):345-532010-06-01 00:00:002019-02-15 09:11:44Immunotherapy of hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-06-01 / J. Mol. Med. 2010 Jun;88(6):589-96
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-06-01 / J. Mol. Med. 2010 Jun;88(6):589-962010-06-01 00:00:002010-06-01 00:00:00Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-06-01 / Expert Rev Respir Med 2010 Jun;4(3):311-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-06-01 / Expert Rev Respir Med 2010 Jun;4(3):311-42010-06-01 00:00:002010-06-01 00:00:00Dendritic cell vaccination as a treatment modality for mesothelioma
